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Abstract
Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate
therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteo-
porosis aged 60 years and over in Italy.
Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with
relevant alternative treatments for postmenopausal osteoporotic women in Italy.
Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the
lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered soluble ALN compared with generic
ALN, denosumab, zoledronic acid and no treatment. Pooled efficacy data derived from the NICE network meta-analysis were
used for bisphosphonate treatments. Two treatment duration scenarios were assessed: 1 year using persistence data derived from
an Italian prospective observational study including 144 and 216 postmenopausal osteoporotic women on buffered soluble ALN
and oral ALN, respectively, and 3 years. Analyses were conducted for women 60–80 years of age with a bone mineral density T-
score ≤ − 3.0 or with existing vertebral fractures.
Results In all simulated populations, buffered soluble ALN was dominant (more QALYs, lower costs) compared to denosumab.
The cost per QALY gained of buffered soluble ALN compared to generic ALN and no treatment always falls below €20,000 per
QALY gained. In the 1-year treatment scenario, zoledronic acid was associated with more QALY than buffered soluble ALN but
the cost per QALY gained of zoledronic acid compared with buffered soluble ALN was always higher than €70,000, while
buffered soluble ALN was dominant in the 3-year treatment scenario.
Conclusion This study suggests that buffered soluble ALN represents a cost-effective strategy compared with relevant alternative
treatments for postmenopausal osteoporosis women in Italy aged 60 years and over.
Keywords Alendronate . Buffered soluble alendronate . Cost-effectiveness . Economic evaluation . Effervescent tablets .
Osteoporosis . Treatment
Introduction
Osteoporosis and related osteoporotic fractures represent a
major health problem worldwide and are on the rise. A recent
study suggested that the total fragility fractures in the largest
five EU countries (UK, Italy, France, Germany and Spain) and
Sweden were estimated to 2.7 million in 2017, resulting in
annual fracture-related costs of €37.5 billion. The number of
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fragility fractures and total costs were further estimated to
increase by 23% and 27%, respectively, by the year 2030. In
addition, the treatment gap (defined as the percentage of eli-
gible individuals not receiving treatment with osteoporosis
drugs) was estimated to be 73% for women, an increase of
17% since 2010 [1].
Oral bisphosphonates (including alendronate (ALN) and
risedronate) remain the most widely used treatment of osteo-
porosis [2]. Poor adherence (defined as the process by which
patients take their medication as prescribed, further divided
into three quantifiable phases: ‘initiation’, ‘implementation’
and ‘discontinuation’ [3]) to oral bisphosphonates is however
a major concern [4], suggesting the need for medications more
cost-effective and more likely to be taken. Approximately
50% of women who initiate oral bisphosphonates discontinue
therapy within 1 year, and patients on oral bisphosphonates
frequently miss doses and therefore do not implement treat-
ment as prescribed [5]. Different barriers to osteoporosis med-
ication adherence have been identified [6], including
treatment-related factors such as medication side effects, com-
plex instructions for medication administration and complex
medication regimens [4, 6]. Oral bisphosphonates require pa-
tients to follow strict dosing instructions to derive the full
benefits, i.e. the intake on an empty stomach at least 30 to
60 min before the first food, drink or other medication of the
day [7].
Recently, buffered soluble ALN 70 mg (Binosto®) was
developed with the aim to improve the gastro-intestinal (GI)
tolerability through full dissolution of ALN in buffered palat-
able solution before ingestion to facilitate passage of the buff-
ered ALN solution into the stomach, minimize the contact of
solid ALN particles with the GI mucosa and buffer the stom-
ach acid with its pH of 4.8–5.4 and thus minimize the risk of
GI irritation [8]. Research has confirmed that buffered soluble
ALN leads to a lower frequency of GI adverse reactions [9]
that could lead to improved adherence.
Considering the limited healthcare resources available, it is
important to assess whether buffered soluble ALN represents
good value for money compared with relevant alternative
treatments. Cost-effectiveness analyses that compare interven-
tions in terms of costs and outcomes are nowadays increas-
ingly important and used by decision makers to efficiently
allocate scarce healthcare resources, especially for pricing
and reimbursement decisions. With the increasing burden of
osteoporosis and development of pharmacological options,
numerous cost-effectiveness studies have been conducted in
last decades to assess the cost-effectiveness of osteoporosis
drugs [10]. However, to our knowledge, no study has yet
estimated the cost-effectiveness of buffered soluble ALN, an
alendronate effervescent tablet.
The aim of this study was therefore to assess the cost-
effectiveness of buffered soluble ALN compared with no
treatment, generic ALN, denosumab and zoledronic acid for
the treatment of postmenopausal women with osteoporosis in
Italy.
Methods
The current study followed the recent ESCEO-IOF recom-
mendations for the conduct and reporting of economic evalu-
ations in osteoporosis [11] and adhered to the Consolidated
Health Economic Evaluation Reporting Standards statement
[12]. A Markov microsimulation model was previously built
and validated to assess the cost-effectiveness of osteoporosis
management in several countries [13–16]. The most recent
version of the model was adapted to the Italian healthcare
context to estimate the cost-effectiveness of buffered soluble
ALN compared with no treatment, generic alendronate,
denosumab and zoledronic acid. The model simulated the en-
tire lifetime of women (up to 100 years old or until death) to
capture relevant costs and health consequences of fracture
events. The model was built up using TreeAge Pro 2020
(TreeAge Pro Inc., Williamston, MA, USA). A description
of the model is provided here below, key model parameters
are included in Table 1 and additional information could be
found in previous publication [15], including an online appen-
dix providing a very detailed explanation of the model [14]. A
list of key model components/assumptions is further provided
in Appendix 1 Table 1.
Model structure
A Markov microsimulation model with a 6-month cycle
length was used to allow tracking patient characteristics and
individual disease histories (e.g. fractures) and avoid unnec-
essary transition restrictions. The model health states were ‘no
fracture’ (where all individuals begin), ‘death’, ‘hip fracture’,
‘clinical vertebral fracture’, ‘wrist fracture’ and ‘other frac-
ture’. The ‘other fracture’ state includes other osteoporotic
fractures as defined by the IOF-EFPIA report [17]. Patients
could experiencemultiple fractures at the same site or multiple
sites. Discount rates of 3% for both costs and health benefits
were used in line with the Italian guideline for economic
evaluations.
Populations
Analyses were conducted at different age (60–80 years) in two
populations with high risk of fragility fractures in line with
reimbursement conditions in Italy (Nota 79): (a) in postmen-
opausal female patients with existing vertebral fracture, and
(b) those with osteoporosis as defined by T-score ≤ − 3.0 at the
femoral neck and without vertebral fracture.
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Fracture risk
Information concerning all hospitalizations occurring in Italy
is registered in hospital discharge records, which are collected
at central level by the Italian Ministry of Health (National
Hospitalization Database). The incidence of hip fractures in
the general Italian population was derived from this database
for the year 2017 for different age groups (65–69, 70–74, 75–
79, 80–84, 85–89, 90–94 and 95+ years) [18]. As these recent
data did not include women aged lower than 65 years, the ratio
of hip fractures between 60–64 and 65–69 years from
Piscitelli et al. [19] for the year 2008 was applied to derive
incidence rate for the age group 60–64 years. To estimate the
incidence of clinical vertebral and wrist fractures, ratios be-
tween hip fracture and clinical vertebral/wrist fractures from
an older Italian database from the year 2008were applied [20].
As no data for other fractures are available at national level in
Italy, we applied the age-specific ratio incidence from other
Table 1 Incidence of fractures, costs, utilities and treatment effects used in the model
Parameter
Incidence of fracture (rate/100)
Hip 0.084 (60–64 y), 0.159 (65–69 y), 0.317 (70–74 y),
0.634 (75–79 y), 1.233 (80–84 y), 2.105 (85–89), 2.804 (90–94), 2.937 (95+)
Vertebral 0.151 (60–64 y), 0.214 (65–69 y), 0.269 (70–74 y), 0.335 (75–79 y),
0.413 (80–84 y), 0.447 (85–89), 0.341 (90–94), 0.248 (95+)
Wrist 0.433 (60–64 y), 0.375 (65–69 y), 0.419 (70–74 y), 0.571 (75–79 y),
0.556 (80–84 y), 0.509 (85–89), 0.406 (90–94), 0.328 (95+)
Other 0.327 (60–64 y), 0.542 (65–69 y), 0.900 (70–74 y), 1.333 (75–79 y),
2.096 (80–84 y), 3.537 (85–89), 4.712 (90–94), 4.935 (95+)
Direct fracture cost (€2019)
Hip, first 6 months 11,151
Hip, yearly long-term 4,130
CV, first 6 months 2,728
Wrist, first 6 months 798
Other, first 6 months 6,176
Health state utility values
General population 0.822
Hip (1st y/subs. y) 0.55 (0.53–0.57)/0.86 (0.84–0.89)
CV (1st y/subs. y) 0.68 (0.65–0.70)/0.85 (0.82–0.87)
Wrist (1st y/subs. y) 0.83 (0.82–0.84)/0.99 (0.97–1.00)
Other (1st y/subs. y) 0.91 (0.88–0.94)/0.99 (0.97–1.00)










Drug and monitoring cost
Buffered soluble ALN 16.18 (monthly)
Generic ALN 13.48 (monthly)
Denosumab 329.25 (6 months)
Zoledronic acid 529.49 (yearly)
GP visit 20.66
BMD measurement 43.36
ALN alendronate, CV clinical vertebral, Subs subsequent, Y years
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countries in line with the methodology used by the IOF-
EFPIA report [17].
Initial probabilities were then adjusted to accurately reflect
the fracture risk in the target population in comparison with
that of the general population using previously validated
methods [21, 22]. The methods calculated the relative risk of
individuals below the threshold value (i.e. BMD T-score ≤ −
3.0) and of individuals with prevalent vertebral fractures com-
pared with that of the general population. Fracture risk was
also adjusted when a new fracture occurred during the simu-
lation process in line with studies suggesting an increased risk
for fracture after a prior fracture [21].
The age-specific mortality rates for the general population
were derived from the Italian Institute of Statistics for the year
2018. An increased mortality after hip fracture and clinical
vertebral fracture was modelled in line with previous studies
[23]. Because excess mortality may also be attributable to
comorbidities, we further took into account that only 25% of
the excess mortality following fractures was attributable to the
fractures themselves [24, 25].
Fracture cost
The healthcare decision maker perspective was used for the
cost estimation. All costs were expressed in €2019 and adjust-
ed using the national price index. The cost of hip fractures was
derived from the study of Piscitelli et al. with data from the
year 2014 [26]. In the absence of local data, the costs of non-
hip fractures were quantified relative to hip fracture in line
with the assumption used in the IOF-EFPIA report [17].
This assumption is conservative compared to a previous
cost-effectiveness study conducted in Italy [27]. Long-term
hip fracture costs were based on the proportion of patients
being institutionalized following the hip fracture, estimated
at 10% in Italy [19, 26], while the annual cost of being in
the nursing home was estimated at €41,300 [28].
Utility values
Utility values were derived from the International Costs and
Utilities Related to Osteoporotic Fractures Study (ICUROS)
study [29]. This study is the largest study assessing the quality
of life of patients with fractures from 11 countries including
2,808 patients, and collected EQ-5D data at different time
points after fractures and a recall before fractures. Baseline
utility data (for patients without fractures) were derived from
the utility estimation before fractures. Decreases in quality of
life as a consequence of fracture were included as utility mul-
tipliers for the first year following fracture and in subsequent
years. Since other fractures were not included in the ICUROS
study, estimate from a previous systematic review was used
[30]. An additional effect on utility after multiple fractures
was modelled [13, 14].
Treatments
In base case, the effects of treatment on the risk of fractures
(expressed as relative risks, RR) were derived from the most
recent network meta-analysis of the National Institute for
Health and Care Excellence (NICE) in the UK (ta464) [31].
In the absence of studies suggesting a clear and significant
difference between bisphosphonates, and in line with the
NICE committee discussion regarding bisphosphonates (ap-
praisal TA464) suggesting that the efficacy estimates of the
oral and intravenous bisphosphonates should be pooled for
each fracture site, results of the network meta-analysis of
poo led bisphosphonates da ta were used for a l l
bisphosphonates including buffered soluble ALN, generic
ALN and zoledronic acid. After stopping medication, it was
assumed a linear decrease of the effects for a duration similar
to the duration of therapy, in line with previous economic
analyses of oral bisphosphonates [10] and clinical data [32].
The effect of denosumab on fracture risk was derived from the
FREEDOM trial [33]. In line with recent evidence suggesting
an immediate bone loss after denosumab discontinuation [34],
an immediate loss of treatment effect following treatment dis-
continuation was assumed.
Two treatment duration scenarios (1 and 3 years) were
assessed and adjusted by medication persistence using a pre-
viously used methodology [35, 36]. Medication persistence
was measured as the probability to be on treatment at different
time points, and has been shown to be the driver of adherence
in economic evaluations in osteoporosis [37]. In the first sce-
nario, treatment duration was set-up to 1 year in line with
persistence data available for buffered soluble ALN derived
from an Italian prospective observational study [38] (see lat-
er). In line with previous literature [39–41], it was assumed
that 90% and 80% of patients under denosumab are persistent
at 6 and 12 months respectively. For patients who
discontinued therapy, treatment cost was stopped and the off-
set time period started immediately. For those who
discontinued oral/effervescent bisphosphonates within 6
months, no treatment effect was received, because at least 6
months of treatment is necessary to reduce the risk of frac-
tures. In the second scenario, a maximum of 3-year treatment
duration was assumed for all treatments to better reflect clin-
ical practices. Real-world persistence data with oral
bisphosphonates were derived from a recent systematic re-
view suggesting that the mean persistence was 53% at 6
months, 46% at 1 year, 37% at 2 years and 31% at 3 years
[42]. Another systematic review of articles published up to
September 2018 identified ten studies reporting zoledronic
acid persistence rates with mean persistence rates of 52%
and 36% for second and third dose, respectively [41].
Denosumab was reported in 19 studies, with mean persistence
rates of 81%, 55% and 35% at second (year 1), fourth and fifth
doses (year 2 and year 2.5) [41]. The (relative) positive effect
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of buffered soluble ALN on persistence at year 1 compared
to oral ALN was assumed to be maintained up to 3 years,
leading to persistence rates for buffered soluble ALN of 83%
at 6 months, 67% at 1 year, 61% at 2 years and 58% at 3
years. Persistence data for both treatment duration scenarios
could be found in Table 2.
The treatments cost included drug costs and costs for
assessment. Drug costs were derived from official listings
from February 2020. We also assigned the cost of one phy-
sician visit (€20.66) every 6 months of treatment (for persis-
tent patients) and the cost of one bone density measurement
(€43.36) at the start of treatment.
In line with previous economic analyses, the risks of gas-
trointestinal effects with alendronate and cellulitis with
denosumab were considered. The assumptions relating to
gastrointestinal effects were chosen to be similar to those
used by the NICE appraisal. It was estimated that patients
treated with ALN required 0.041 extra physician consulta-
tions during the first cycle (6 months) and 0.021 physician
consultations during the following cycles on treatment, as
well as a proton-pump inhibitor (PPI) for each visit.
Despite studies suggested lower frequency of GI disorders
with buffered soluble ALN, we conservatively assumed than
buffered soluble ALN and generic ALN are associated with
similar side effects in the base case. The rate of skin infections,
including cellulitis, was reported more frequently with
denosumab in the FREEDOM trial, i.e. 0.0031 annually, and
was included in the analysis.
Persistence data
The Italian observational study included postmenopausal
women from a standardized clinical database with BMD T-
score < − 2.5, or between − 2 and − 2.5 and at least one
vertebral fracture, starting buffered soluble ALN between
July 2015 and June 2016. A historical cohort comprised of
randomly selected and age-matched women on conventional
ALN tablet was used as a control. Persistence at 6 and 12
months was estimated between the two groups.
Analyses
A total of 1,000,000 trials was run for each analysis. Total
costs, disaggregated costs (i.e. treatment costs and fracture-
related costs) and accumulated QALYs were estimated for
each treatment. If buffered soluble ALN is associated with
more QALYs and lower costs than an alternative treatment,
buffered soluble ALN is considered dominant or cost-saving
(when compared to no treatment). If buffered soluble ALN
provides more QALYs and more costs, then we computed
the incremental cost-effectiveness ratio (ICER) defined as
the difference between buffered soluble ALN and the compar-
ator treatment in terms of total costs (expressed in €2019)
divided by the difference between them in terms of QALYs.
If the ICER is above the cost-effectiveness threshold, then the
cost is too high for the benefits and the intervention is not
considered as cost-effective. In Italy, no specific threshold is
actually used for defining cost-effectiveness. Borgström et al.
[43] have suggested a threshold for QALY equal to two times
the gross domestic product per capita for industrialized coun-
tries (±€70,000 in Italy). This assumption has been used for
defining fracture risk thresholds in several countries [44].
Sensitivity analyses were then performed to assess the im-
pact of model parameters on the results. One-way sensitivity
analyses assessed the impact of single parameters on the re-
sults and were conducted on discount rates, fracture costs,
fracture risks, fracture disutility, mortality and treatment costs.
Sensitivity analyses were also conducted on varying by ± 25%
the discontinuation rates of buffered soluble ALN and by re-
ducing by half side effects associated with buffered soluble
ALN. We also conducted another sensitivity analysis where
treatment-specific efficacy data were derived from other
sources. For ALN (used in our study for both generic ALN
and buffered soluble ALN), data from the article of Black et al.
(2000) were used [45]. Data of women with existing vertebral
fracture were specifically used for this population, and data
from women without vertebral fracture and femoral T-score <
− 2.5 were used in the model for women with a T-score < −
3.0. The effects of zoledronic acid were derived from the
HORIZON-FT trial [46], and the effects of denosumab were
derived from a post hoc analysis of the FREEDOM trial in
women with higher risk of fractures [47].
Table 2 Persistence data used in both treatment duration scenarios
1-year treatment scenario
6 months Year 1
Buffered soluble ALN [38] 91% 81%
Generic ALN [38] 75% 69%
Denosumab [41] 90% 81%
Zoledronic acid 100% *
3-year treatment scenario
6 months Year 1 Year 2 Year 3
Buffered soluble ALN [38, 42] 83% 67% 61% 58%
Generic ALN [42] 53% 46% 37% 31%
Denosumab [41] 90% 81% 55% 35%**
Zoledronic acid [41] 100% 52% 36% 36%***
In the 1-year treatment scenario, persistence data for buffered soluble
ALN and generic ALN were derived from Giusti et al. [38], while data
for the 3-year treatment scenario were derived from the literature review
of Fatoye et al. [42] for ALN and were adjusted for buffered soluble ALN
based on improved persistence from Giusti et al. [38]
*Persistence of zoledronic acid was optimal (100%) in the 1-year treat-
ment scenario
**35% was also used at 30 months based on Koller et al. [41]
***Assumed to be similar at 24 months (from Koller et al. [41])
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Finally, probabilistic sensitivity analyses were undertaken
to examine the effect of the joint uncertainty surrounding the
model variables. Nearly all parameters were modified simul-
taneously over plausible range of values, following guidelines
and in line with previous studies (see Appendix 1 Table 2).
For each probabilistic sensitivity analysis, the model was run
200 times based on runs of 50,000 patients per treatment arm.
Results were presented in the form of cost-effectiveness ac-
ceptability curves that show the probability of being cost-
effective as a function of the decision maker’s willingness to
pay per QALY gained.
Results
Persistence data
A total of 360 postmenopausal women were included in the
retrospective study; 144 were treated with buffered soluble
ALN and 216 with conventional ALN tablet. The study re-
vealed that a significantly higher number of women were per-
sistent at 6 months and 12 months with buffered soluble ALN
(91% and 81% respectively) compared to 75% and 69% of
patients with conventional ALN tablet, respectively.
Base-case analysis
Table 3 presents the total and disaggregated healthcare costs,
accumulated QALYs and the ICER (expressed in cost per
QALY gained) of buffered soluble ALN compared with no
treatment, generic ALN, denosumab and zoledronic acid in
women aged 70 years. In the 1-year treatment scenario, in
women with prevalent vertebral fractures, the incremental
treatment cost (including drug cost adjusted by persistence
and monitoring costs) between buffered soluble ALN and
generic alendronate was €50, while the improved persistence
of buffered soluble ALN leads to a saving of €39 resulting
from more prevented fractures due to the improved persis-
tence. The incremental total healthcare cost was thus estimat-
ed at +€11 (50–39) and buffered soluble ALN was associated
with a QALY gain of 0.0028. The cost per QALY gained of
buffered soluble ALN compared to generic alendronate was
thus estimated at €4,028 (11/0.0028) per QALY gained.
Compared to DMAB, buffered soluble ALN was associated
with more QALYs and lower costs, being therefore dominant.
Zoledronic acid is associated with more QALY than buffered
soluble ALN; however, the cost per QALY gained of zoledro-
nic acid (€121,514 per QALY gained) is higher than common-
ly accepted cost-effectiveness thresholds, meaning that zole-
dronic acid is not cost-effective compared to buffered soluble
ALN. In women with BMD T-score ≤ − 3.0, buffered soluble
ALN was dominant (more QALYs and lower costs) than ge-
neric alendronate and denosumab. In addition, buffered
soluble ALN was cost-saving (more QALYs, lower total
costs) compared to no treatment, and the cost per QALY
gained of zoledronic compared to buffered soluble ALN was
also higher than cost-effectiveness threshold, meaning that
buffered soluble ALN is the most cost-effective option. In
the 3-year treatment scenario, buffered soluble ALN was
shown to be dominant compared to both denosumab and zo-
ledronic acid in both populations. Buffered soluble ALN was
also shown to be cost-saving and dominant compared to ge-
neric ALN in women with BMD T-score ≤ − 3.0.
In Table 4, the ICERs of buffered soluble ALN compared
to all alternative treatments are presented for other ages rang-
ing from 60 to 80 years. Appendix 2 Tables 1and 2 a-f provide
the lifetime costs and QALYs for all these age-specific simu-
lations. Compared to denosumab, buffered soluble ALN was
always dominant (more QALYs, lower costs). The cost per
QALY gained of buffered soluble ALN compared to generic
ALN and no treatment falls always below €20,000 per QALY
gained. In women aged 75 years and older with prevalent
vertebral fractures and in women aged 65 years and older with
T-score ≤ − 3.0, buffered soluble ALN was even shown to be
dominant (more QALYs, lower costs) compared to generic
alendronate and no treatment. In the 1-year treatment scenario,
zoledronic acid was associated with more QALY than buff-
ered soluble ALN but the cost per QALY gained of zoledronic
acid compared to buffered soluble ALN was always higher
than €70,000 per QALY gained, meaning that zoledronic acid
is not cost-effective, while buffered soluble ALN was shown
to be dominant compared to zoledronic acid in the 3-year
treatment scenario.
Sensitivity analyses
Table 5 reports the results of the one-way sensitivity analyses
in women aged 70 years with BMD T-score ≤ − 3.0 in the 1-
year treatment scenario. In most analyses, buffered soluble
ALN remained dominant (more QALYs, lower costs) com-
pared to generic ALN and denosumab, and cost-saving com-
pared to no treatment. The ICERs of buffered soluble ALN
were shown to be in particular affected by fracture costs and
discontinuation rates of buffered soluble ALN. In all the sen-
sitivity analyses, buffered soluble ALN remained cost-
effective compared to all treatments except when using other
treatment-specific efficacy data where the ICER of zoledronic
acid fall below the threshold of €70,000 per QALY gained.
The results of the probabilistic sensitivity analyses are pro-
vided in Fig. 1 where the cost-effectiveness acceptability
curves show the probability that each intervention is cost-
effective for different willingness to pay of decision makers
per QALY gained. The curves suggest that buffered soluble
ALN is the most cost-effective intervention for willingness to
pay between €5,000 and €75,000 per QALY gained in the 1-
year treatment xscenario. At a threshold of €45,000 per
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QALY gained, in women aged 70 years with BMD T-score ≤
− 3.0, buffered soluble ALN was cost-effective in 56% of the
simulations compared to 6% for DMAB, 10% for generic
alendronate and 26% for zoledronic acid. In the 3-year treat-
ment scenario, buffered soluble ALN was the most cost-
effective treatment for any willingness to pay.
Cost-effectiveness acceptability curve of buffered soluble
ALN compared to individual treatments could be found in
Appendix 2 Fig. 2 a, b, c, d for women with BMD T-score
≤ − 3.0 aged 70 years. Buffered soluble ALN was the most
cost-effective intervention compared to all individual treat-
ments. By example, at a threshold of €45,000 per QALY
gained, in the 1-year treatment scenario, buffered soluble
ALN was cost-effective in 100% of the simulations compared
to no treatment, in 84% compared to generic alendronate, in
92% compared to denosumab and 71% compared to zoledro-
nic acid.
Discussion
In the current research, we assessed the cost-effectiveness of
buffered soluble ALN compared with relevant alternative
treatments for postmenopausal osteoporotic women in Italy.
Two treatment duration scenarios were assessed: a 1-year
treatment scenario in line with available persistence data and
a 3-year treatment scenario to better reflect clinical practices,
extrapolating the 1-year persistence benefit of buffered solu-
ble ALN up to 3 years. The results indicated that in both
scenarios, buffered soluble ALN represents a cost-effective
strategy compared with generic ALN, zoledronic acid,
denosumab and no treatment for the treatment of postmeno-
pausal women with osteoporosis in Italy aged 60 years and
over. More specifically, buffered soluble ALN was shown to
be dominant (more QALYs, lower costs) compared to
denosumab. The cost per QALY gained of buffered soluble
Table 3 Lifetime healthcare costs, QALYs, and incremental cost-effectiveness ratio (cost (2019€) per QALY gained) of buffered soluble ALN
compared with no treatment, generic alendronate, denosumab and zoledronic acid at the age of 70 years
Buffered soluble ALN No treatment Generic ALN Denosumab Zoledronic acid
(A) 1-year treatment scenario
BMD T-score ≤ − 3.0
Treatment cost 270 0 220 696 602
Fracture-related cost 15,375 15,683 15,429 15,415 15,335
Total healthcare cost* 15,644 15,683 15,649 16,111 15,937
QALY 10.3629 10.3434 10.3601 10.3607 10.3653
ICER (€ per QALY gained) Cost-saving Dominant Dominant 122,769**
Prevalent vertebral fractures
Treatment cost 270 0 220 696 602
Fracture-related cost 11,698 11,891 11,737 11,724 11,674
Total healthcare cost 11,968 11,891 11,957 12,420 12,276
QALY 10.4005 10.3794 10.3977 10.3987 10.4030
ICER (€ per QALY gained) 3,668 4,028 Dominant 121,514**
(B) 3-year treatment scenario
BMD T-score ≤ − 3.0
Treatment cost 575 0 358 1,493 1,082
Fracture-related cost 14,979 15,718 15,253 15,121 15,053
Total healthcare cost* 15,554 15,718 15,610 16,614 16,135
QALY 10.3880 10.3445 10.3723 10.3805 10.3840
ICER (€ per QALY gained) Cost-saving Dominant Dominant Dominant
Prevalent vertebral fractures
Treatment cost 575 0 358 1,493 1,082
Fracture-related cost 11,425 11,861 11,590 11,508 11,476
Total healthcare cost 11,999 11,861 11,948 13,001 12,558
QALY 10.4299 10.3840 10.4138 10.4252 10.4264
ICER (€ per QALY gained) 3,019 3,189 Dominant Dominant
Dominant = buffered soluble ALN more QALYs, lower costs. Cost-saving = buffered soluble ALN more QALY and lower costs than no treatment
ALN alendronate, QALY quality-adjusted life-years
*The total healthcare costs are the sum of treatment cost and fracture-related costs
**ICER of zoledronic acid vs buffered soluble ALN
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ALN compared to generic alendronate and no treatment al-
ways falls below €20,000 per QALY gained. In women aged
75 years and older with prevalent vertebral fractures and in
women aged 65 years and older with T-score ≤ − 3.0, buffered
soluble ALN was even shown to be dominant (more QALYs,
lower costs) compared to generic alendronate and no treat-
ment. In the 1-year treatment scenario, one yearly zoledronic
acid was associatedwith full persistence and thusmoreQALY
than buffered soluble ALN but the cost per QALY gained of
zoledronic acid compared to buffered soluble ALNwas higher
than the cost-effectiveness threshold. In the 3-year treatment
scenario, buffered soluble ALN was shown to be dominant
compared to zoledronic acid.
To our knowledge, this study provides the first results
about the cost-effectiveness of an effervescent alendronate
for the treatment of postmenopausal women with
osteoporosis. Buffered soluble ALN effervescent tablet
was shown to be associated to a lower frequency of GI
adverse reactions and greater medication persistence [9,
38]. Based on this improved persistence, our economic
analysis suggests that the additional health benefits of buff-
ered soluble ALN are worth for the additional drug cost
compared to generic ALN [13]. Our analysis also sug-
gested that buffered soluble ALN was associated with bet-
ter outcomes and lower total costs than denosumab,
resulting mainly from the absence of effects after discon-
tinuation with denosumab. Recent evidence has indeed
suggested an immediate bone loss after denosumab discon-
tinuation and increased risk of vertebral fractures [34].
The results of the current study have to be interpreted
within the context of some limitations. First, persistence
data to buffered soluble ALN and generic alendronate were
Table 4 Incremental cost-effectiveness ratio (cost (€) per QALY gained) of buffered soluble ALN compared with no treatment, generic alendronate,
denosumab and zoledronic acid for women aged 60-80 years
Buffered soluble ALN
vs no treatment vs generic ALN vs denosumab vs zoledronic acid
(A) 1-year treatment scenario
BMD T-score ≤ − 3.0
60 years 7,058 8,774 Dominant 236,003**
65 years Cost-saving Dominant Dominant 100,064**
70 years Cost-saving Dominant Dominant 122,769**
75 years Cost-saving Dominant Dominant 74,171**
80 years Cost-saving Dominant Dominant 87,453**
Prevalent vertebral fractures
60 years 12,699 15,322 Dominant 128,098**
65 years 7,448 8,239 Dominant 133,339**
70 years 3,668 4,028 Dominant 121,514**
75 years Cost-saving Dominant Dominant 77,693**
80 years Cost-saving Dominant Dominant 71,467**
(B) 3-year treatment scenario
BMD T-score ≤ − 3.0
60 years 4,356 5,347 Dominant Dominant
65 years Cost-saving Dominant Dominant Dominant
70 years Cost-saving Dominant Dominant Dominant
75 years Cost-saving Dominant Dominant Dominant
80 years Cost-saving Dominant Dominant Dominant
Prevalent vertebral fractures
60 years 13,290 12,949 Dominant Dominant
65 years 6,761 6,753 Dominant Dominant
70 years 3,019 3,189 Dominant Dominant
75 years Cost-saving Dominant Dominant Dominant
80 years Cost-saving Dominant Dominant Dominant
ALN = alendronate, Dominant = buffered soluble ALN more QALYs, lower costs. Cost-saving = buffered soluble ALN more QALY and lower costs
than no treatment
**ICER of zoledronic acid vs buffered soluble ALN
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Table 5 One-way sensitivity analyses on the incremental cost-effectiveness ratio of buffered soluble ALN compared with no treatment, generic
alendronate, denosumab and zoledronic acid in women aged 70 years with BMD T-score ≤ − 3.0 (1-year treatment duration scenario)
Buffered soluble ALN
vs no treatment vs generic ALN vs denosumab vs zoledronic acid
Base case Cost-saving Dominant Dominant 122,769**
Fracture costs 25% lower 2,006 3,691 Dominant 108,185**
Fracture costs 25% higher Cost-saving Dominant Dominant 158,384**
Fracture disutilities 25% higher Cost-saving Dominant Dominant 185,290**
Fracture disutilities 25% lower Cost-saving 309 Dominant 79,316**
Discount rates 0% Cost-saving Dominant Dominant 74,618**
Discount rates 5% Cost-saving 892 Dominant 114,875**
Excess mortality (50%) Cost-saving 306 Dominant 98,119**
Buffered soluble ALN cost + 10% Cost-saving 204 Dominant 84,429**
Buffered soluble ALN cost − 10% Cost-saving Dominant Dominant 158,934**
Buffered soluble ALN side effects − 50% Cost-saving Dominant Dominant 123,061**
Buffered soluble ALN discontinuation rates + 25% Cost-saving 5,031 Dominant 115,012**
Buffered soluble ALN discontinuation rates − 25% Cost-saving Dominant Dominant 130,526**
Alternative treatment efficacy Cost-saving Dominant 140,456** 36,351**

















































































Willingness to pay (€ per QALY gained)
(1)
Buffered soluble ALN Denosumab


















































































Willingness to pay (€ per QALY gained)
(2)
Buffered soluble ALN Denosumab
Generic ALN No treatment
Zoledronic acid
Fig. 1 Cost-effectiveness
acceptability curves of buffered
soluble ALN compared with no
treatment, generic ALN,
denosumab and zoledronic acid in
women aged 70 with BMD T-
score ≤ − 3.0; (1) 1-year treatment
scenario and (2) 3-year treatment
scenario
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derived from one study with a total sample of 360 with
similar characteristics than patients assessed in this eco-
nomic study, and up to 1 year. Furthermore, the 1-year
persistence benefit of buffered soluble ALN compared to
oral ALN was extrapolated in the 3-year treatment scenar-
io. Further studies with larger sample and longer follow-up
would be needed to confirm the (long-term) persistence
benefits of buffered soluble ALN. It is also important to
acknowledge that persistence data and drug cost were de-
rived from Binosto® buffered soluble ALN, and our find-
ing could therefore not be applied to other formulation of
ALN. Furthermore, it would be interesting to assess per-
sistence for all medications in the same population. As
patients on denosumab should continue denosumab thera-
py for up to 10 years or be switched to an alternative treat-
ment (such as a bisphosphonate therapy) [48], long-term
(sequential) treatment scenarios would also be interesting.
Second, our economic analysis was conducted in wom-
en with BMD T-score ≤ − 3.0 or with existing vertebral
fractures in line with current reimbursement criteria for
osteoporotic treatments in Italy. Further assessment of the
cost-effectiveness of buffered soluble ALN in other popu-
lations (e.g. based on FRAX® score, or in patients with an
imminent risk fracture) could be interesting. Other poten-
tial limitations are related to the model and data. The most
important are availability of data. Although data used to
construct the model were based on Italian literature when-
ever possible, some data were derived from other coun-
tries. In particular, no utility values were available in
Italy and were therefore derived from the largest multina-
tional study assessing the effects of fractures on quality of
life (ICUROS). Conservative assumptions were further
used for the cost of non-hip fractures. Support of an
Italian expert and contact with the Italian National
Institute of Health also helped to identify the best available
data.
On the other hand, some assumptions were conservative
for buffered soluble ALN treatment. First, similar side ef-
fects for buffered soluble ALN and generic alendronate
were assumed, despite that buffered soluble ALN was as-
sociated with a lower frequency of GI adverse reactions
[9]. A sensitivity analysis reducing by 50% side effects
of buffered soluble ALN revealed however a very small
effect of side effects on the ICER. Second, persistence data
from the Italian observational database were derived for
branded alendronate and used for the generic formulation
in our economic study. Previous studies have suggested
that persistence to generic formulations is even poorer than
for branded formulations [49].
In conclusion, this study provides the first economic
analysis of a buffered soluble ALN effervescent tablet,
suggesting that buffered soluble ALN may represent a
cost-effective strategy compared with relevant alternative
treatments for the treatment of postmenopausal women
with osteoporosis in Italy aged 60 years and over.
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